Abstract
Fungal infections afflict an increasing number of patients due to increases in susceptible immunosuppressed populations such as those receiving chemotherapy, transplant conditioning or infections such as HIV. Poor responses to available therapy have prompted searches for novel drug targets, but screens can be difficult as expression of these targets often relies on specific inducing conditions present within the mammalian host. Cryptococcus is a yeast-like basidiomycete fungus capable of causing fatal cryptococcocis in both immunocompetent and immunocompromised individuals, and is currently the fourth cause of infectious death in regions of Sub-Sahara Africa, excluding HIV. A key virulence factor of Cryptococcus is a cell-wall laccase, which produces melanin in the presence of exogenous catecholamines. Screening melanin-deficient strains of the fungus is facile and has identified cellular processes critical for virulence including copper homeostasis and autophagy. As demonstrated here through the analysis of laccase regulatory networks of Cryptococcus, genetic analysis targeting virulence-associated regulatory pathways can lead to the discovery of promising novel drug candidates against fungal species.
Keywords: AIDS, biological markers, clinical markers, Cryptococcus, drug design, laccase, regulation, review.
Current Enzyme Inhibition
Title:Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus
Volume: 9 Issue: 2
Author(s): Jennifer Rabjohns and Peter R. Williamson
Affiliation:
Keywords: AIDS, biological markers, clinical markers, Cryptococcus, drug design, laccase, regulation, review.
Abstract: Fungal infections afflict an increasing number of patients due to increases in susceptible immunosuppressed populations such as those receiving chemotherapy, transplant conditioning or infections such as HIV. Poor responses to available therapy have prompted searches for novel drug targets, but screens can be difficult as expression of these targets often relies on specific inducing conditions present within the mammalian host. Cryptococcus is a yeast-like basidiomycete fungus capable of causing fatal cryptococcocis in both immunocompetent and immunocompromised individuals, and is currently the fourth cause of infectious death in regions of Sub-Sahara Africa, excluding HIV. A key virulence factor of Cryptococcus is a cell-wall laccase, which produces melanin in the presence of exogenous catecholamines. Screening melanin-deficient strains of the fungus is facile and has identified cellular processes critical for virulence including copper homeostasis and autophagy. As demonstrated here through the analysis of laccase regulatory networks of Cryptococcus, genetic analysis targeting virulence-associated regulatory pathways can lead to the discovery of promising novel drug candidates against fungal species.
Export Options
About this article
Cite this article as:
Rabjohns Jennifer and Williamson R. Peter, Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus, Current Enzyme Inhibition 2013; 9 (2) . https://dx.doi.org/10.2174/1573408011309020006
DOI https://dx.doi.org/10.2174/1573408011309020006 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analysis of the Molecular Determinants of the Response of Chronic Myelogenous Leukaemia to Tyrosine Kinase Inhibitors
Current Pharmacogenomics Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?
Reviews on Recent Clinical Trials Treatment of High-Grade Pelvic-Type Serous Carcinomas (Ovary, Fallopian Tube and Peritoneum): Current Therapeutic Paradigms, Prospects, and Challenges
Current Cancer Therapy Reviews Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Treatment Approaches in Elderly Patients with Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry FLT3 Inhibitors in the Management of Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Snake Venom Induced Local Toxicities: Plant Secondary Metabolites as an Auxiliary Therapy
Mini-Reviews in Medicinal Chemistry Chemoprotection and Selection by Chemotherapy of Multidrug Resistance-associated Protein-1 (MRP1) Transduced Cells
Current Gene Therapy Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Erythropoietic Porphyrias: Animal Models and Update in Gene-Based Therapies
Current Gene Therapy New Therapies for Patients with Chronic Lymphocytic Leukemia
Current Cancer Therapy Reviews Natural and Synthetic Furanocoumarins as Treatment for Vitiligo and Psoriasis
Current Drug Therapy